BioLife Solutions to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 26, 2026
Rhea-AI Summary
BioLife Solutions (NASDAQ: BLFS) will report Q4 and full-year 2025 financial results on February 26, 2026 and hold a conference call and live webcast at 4:30pm ET (1:30pm PT).
Investors can access the live webcast on the company Investor Relations website and a replay will be archived for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – BLFS
In the Feb 17 session, BLFS gained 0.58%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Supply agreement | Positive | -3.0% | Exclusive and non-exclusive Qkine cytokine distribution deal for CGT market. |
| Jan 12 | Prelim revenue update | Positive | -3.3% | Preliminary Q4 and FY 2025 revenue growth above raised guidance range. |
| Nov 20 | Facility opening | Positive | -0.7% | Launch of Aby J. Mathew Center to support biopreservation R&D and training. |
| Nov 17 | Conference participation | Positive | -0.3% | Participation in multiple late-2025 investor conferences and updated presentation. |
| Nov 06 | Q3 2025 earnings | Positive | -2.0% | Strong Q3 cell processing growth, higher guidance, and evo business sale. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive updates have been followed by negative next-day price reactions, indicating a pattern of selling into good news.
Over the last several months, BioLife Solutions reported strong operational progress, including Q3 2025 revenue of $28.1M with 31% YoY growth and adjusted EBITDA of $7.8M, the sale of its evo cold chain business for $25.5M, and preliminary 2025 revenue from continuing operations of $96.2M, slightly above raised guidance. It also expanded via a multi-year Qkine supply agreement and opened the Aby J. Mathew Center for Biopreservation Excellence. Despite these positive developments, shares often traded down the day after such announcements, providing important context for the upcoming full-year 2025 earnings release date.
Key Terms
cell and gene therapy medical
cgt medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free 1-833-630-0431 or 1-412-317-1808 for international callers. A webcast replay will be available approximately two hours after the call and will be archived on https://investors.biolifesolutions.com for 90 days.
About BioLife Solutions
BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit www.biolifesolutions.com or follow BioLife on LinkedIn and X.
Media & Investor Relations
At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com
Investors
Alliance Advisors IR
Jody Cain
(310) 691-7100
jcain@allianceadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-update-on-february-26-2026-302688869.html
SOURCE BioLife Solutions, Inc.